CORRESPONDENCE

The Use of Rapid Tranquilization in Aggressive Behavior

by Dr. med. Sophie Hirsch and B. Sc., Prof. Dr. med. Tilman Steinert in issue 26/2019

Therapeutic Drug Monitoring

In their article, our colleagues Hirsch and Steinert (1) provide an important overview of the emergency medical treatment of psychomotor agitation and aggressive behavior. Another important aspect in this context is therapeutic drug monitoring (TDM) of antipsychotics and antidepressants. This is especially true, as the authors list problems such as the low potency, adverse drug reactions, and dose adjustments for geriatric patients, as well as drug–drug interactions, pharmacokinetic peculiarities, and individual enzyme features. Furthermore, individualized TDM is an important component of emergency medical treatment and follow-up treatment. TDM is performed according to the latest developments using liquid chromatography tandem mass spectrometry (LC-MS/MS), to obtain the best possible sensitivity and specificity while avoiding cross-reactivity in the analysis. Recommendations for TDM can be found in the currently valid version of the guideline of the working group on neuropsychopharmacology and pharmacopsychiatry (*Arbeitsgemeinschaft fuer Neuropsychopharmakologie und Pharmakopsychiatrie*) (2).

DOI: 10.3238/arztebl.2019.0691a

References

1. Hirsch S, Steinert T: The use of rapid tranquilization in aggressive behavior. *Dtsch Arztebl Int* 2019; 116: 445–52.
2. Hiemke C, Bergemann N, Clement HW, et al.: AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2017; *Pharmacopsychiatry* 51: 9–62.

Dr. med. Ramona Dolscheid-Pommerich

Prof. Dr. med. Dipl. Biol. Birgit Stoffel-Wagner

Institut für Klinische Chemie und Klinische Pharmakologie
Universitätsklinikum Bonn
ramona.dolscheid-pommerich@ukbonn.de

Conflict of interest statement

Dr. Dolscheid-Pommerich has received speaking honoraria from Siemens Healthineers and Roche Diagnostics.

Prof. Stoffel-Wagner declares that no conflict of interest exists.

In Reply:

A detailed laboratory analysis is usually not feasible in the emergency situations that we describe (1), in which an unknown patient with severe mental or somatic illness is presented to a rescue service, an emergency department, or a psychiatric clinic, posing an acute danger. Nonetheless, such situations often require therapy to be immediately initiated, while results from therapeutic drug monitoring can sometimes take several days. Furthermore, as patients are often uncooperative and do not agree to blood sampling, physicians have to limit themselves to a short physical examination, medical history (often reported by others), and, if possible, a blood glucose test (2). In the further course of treatment, laboratory tests including therapeutic drug monitoring are certainly indicated, in particular if relapsing aggressive behavior occurs despite the therapy and if high-dose monotherapy or antipsychotic polypharmacy appear necessary (3, 4).

DOI: 10.3238/arztebl.2019.0691b

References

1. Hirsch S, Steinert T: The use of rapid tranquilization in aggressive behavior. *Dtsch Arztebl Int* 2019; 116: 445–52.
2. Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V. (DGPPN): Verhinderung von Zwang: Prävention und Therapie aggressiven Verhaltens bei Erwachsenen. S3-Leitlinie 2018. www.awmf.org/uploads/tx_szleitlinien/038-022l_S3_Verhinderung-von-Zwang-Praevention-Therapie-aggressiven-Verhaltens_2018-11.pdf (last accessed on 5 August 2019)
3. Meyer JM: A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. *CNS Spectr* 2014; 19: 432–8.
4. Morrisette DA, Stahl SM: Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. *CNS Spectr* 2014; 19: 439–48.

Dr. med. Sophie Hirsch, B. Sc.

Prof. Dr. med. Tilman Steinert

ZfP Südwürttemberg
Klinik für Psychiatrie und Psychotherapie I der Universität Ulm
sophie.hirsch@zfp-zentrum.de; tilman.steinert@zfp-zentrum.de

Conflict of interest statement

The authors declare that no conflict of interest exists.